A PHASE 1 STUDY OF MILADEMETAN IN COMBINATION WITH QUIZARTINIB IN SUBJECTS WITH FLT3-ITD MUTANT ACUTE MYELOID LEUKEMIA THAT ARE RELAPSED/REFRACTORY OR NEWLY DIAGNOSED AND UNFIT FOR INTENSIVE CHEMOTHERAPY

Brief description of study

To determine the safety and tolerability of the drug combination, identification of the optimum dosing schedule, MTD, and the recommended dose for expansion cohort (RDE). Part 2 (Dose Expansion): To confirm safety and tolerability of the combination therapy at RDE and identify the recommended Phase 2 dose.


Clinical Study Identifier: s19-00590
ClinicalTrials.gov Identifier: NCT03552029
Principal Investigator: Mohammad Maher Abdul Hay.


If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.